HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care
Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.
Managing HER2+ Breast Cancer With Leptomeningeal Metastases
Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.
Agents in Development for HER2+ Breast Cancer
Experts share brief insights on novel agents in development for HER2+ breast cancer and consider how they may impact the treatment landscape.
Optimizing Care of Patients on T-DXd for HER2+ mBC With CNS Disease
Centering discussion on trastuzumab deruxtecan use in HER2+ metastatic breast cancer, experts elucidate adverse event management and concurrent radiation therapy.
HER2+ Metastatic Breast Cancer: Guidance on MRI Use After CNS Radiation
A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.
Patient Case 3: HER2+ Metastatic Breast Cancer With CNS Disease
Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.
Novel Combination Strategies in HER2+ Metastatic Breast Cancer With CNS Disease
Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.
HER2+ mBC With CNS Disease: Sequencing Therapy After Progression on Tucatinib
Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.
HER2CLIMB: Role of Tucatinib in Treating HER2+ mBC With CNS Disease
A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.
HER2+ Metastatic Breast Cancer: Role of Radiation Therapy in Managing CNS Disease
Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.
Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease
Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.
Patient Case 2: HER2+ Breast Cancer With CNS Metastases
Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.
Strategies to Identify and Delay Brain Metastases in HER2+ Breast Cancer
A brief review on how best to identify, delay, or avoid brain metastases in patients diagnosed with metastatic HER2+ breast cancer.
HER2+ Metastatic Breast Cancer: Factors in Selecting Optimal Therapy
Having outlined available treatment options for patients with HER2+ metastatic breast cancer, expert panelists share which factors help to select optimal therapy.
Treatment Armamentarium for HER2+ Metastatic Breast Cancer
Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.
Patient Case 1: Patient With HER2+ Metastatic Breast Cancer and no CNS Disease
Expert panelists open their discussion on HER2+ breast cancer by reviewing a patient case of metastatic disease with no CNS involvement.
